Clinical trials
catalyst calendar across sponsors →Studies where VRDN is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
8 interventional · 4 with posted results
Held by 10 tracked-famous managers (Point72 Asset Management, L.P., Balyasny Asset Management L.P., D. E. Shaw & Co., Inc., Schonfeld Strategic Advisors LLC, RENAISSANCE TECHNOLOGIES LLC, +5 more) · FINRA short interest 11.3 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Updated |
|---|---|---|---|---|---|---|---|
| A Safety and Tolerability Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)NCT06812325Treatment Emergent Adverse Event (TEAE) incidence rate through Week 24Randomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: VRDN-003, Placebo | Thyroid Eye Disease (TED) | 320 | 2026-04-22actual | 2026-05-22 |
| An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Chronic Thyroid Eye Disease (TED)NCT06625398Title: Proptosis Responder Rate in the most proptotic eye as measured by exophtalmometerRandomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: VRDN-003, Placebo | Thyroid Eye Disease | 204 | 2026-03-04actual | 2026-08-18 |
| An Efficacy, Safety, and Tolerability Study of VRDN-003 in Participants With Active Thyroid Eye Disease (TED)NCT06625411Proptosis Responder Rate in the most proptotic eye as measured by exophtalmometerRandomized · Triple-masked · Treatment | Phase 3 | Active, not recruiting | Drug: VRDN-003, Placebo | Thyroid Eye Disease | 132 | 2026-02-12actual | 2026-08-18 |
| A Safety, Tolerability and Pharmacokinetics Study of VRDN-003 in Participants With Thyroid Eye Disease (TED)NCT07155668Treatment Emergent Adverse Event (TEAE) incidence rateRandomized · Open-label · Treatment | Phase 3 | Completed | Drug: VRDN-003 · Device: Autoinjector | Thyroid Eye Disease | 87 | 2026-05-28actual | 2026-06-25 |
| A Randomized, Controlled, Safety and Tolerability Study of VRDN-001 in Participants With Thyroid Eye Disease (TED)NCT06384547results2026-08-13Number of Participants With Treatment-emergent Adverse Events (TEAEs) Through Week 15Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Veligrotug | Thyroid Eye Disease | 231 | 2025-05-01actual | 2026-08-13 |
| An Open-label Study (OLE) for Non-responders of VRDN-001-101 and VRDN-001-301NCT06179875results2026-08-14Proptosis Responder Rate (PRR) in the Most Proptotic Eye as Measured by ExophthalmometerOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Veligrotug | Thyroid Eye Disease | 139 | 2025-04-25actual | 2026-08-14 |
| An Efficacy, Safety, and Tolerability Study of Veligrotug (VRDN-001), in Participants With Chronic Thyroid Eye Disease (TED)NCT06021054results2026-08-13Proptosis Responder Rate (PRR) in the Most Proptotic Eye as Measured by ExophthalmometerRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Veligrotug, Placebo | Thyroid Eye Disease | 188 | 2024-11-04actual | 2026-08-13 |
| A Safety, Tolerability, and Efficacy Study of Veligrotug (VRDN 001) in Participants With Thyroid Eye Disease (TED)NCT05176639results2026-08-13Proptosis Responder Rate (PRR) in the Study Eye As Measured by ExophthalmometerRandomized · Triple-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Veligrotug, Placebo | Thyroid Eye Disease | 113 | 2024-07-15actual | 2026-08-13 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19